Prognostic analysis of nimotuzumab combined with concurrent chemoradiotherapy for locally advanced cervical cancer: a multicenter real-world study.

Jiwei Li, Tao Wu, Manbo Cai, Changjun Xie, Sijuan Ding, Wen Zou, Jia Yao, Jingjing Wang

Abstract readMulticenter Study

In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiwei Li *Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, China.

Tao Wu *Department of Oncology, Xiangya School of Medicine, Changde Hospital, Changde, China.

Manbo CaiDepartment of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.

Changjun XieDepartment of Oncology, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.

Sijuan DingDepartment of Oncology, The central hospital of Yongzhou, Yongzhou, China.

Wen ZouDepartment of Oncology, The Second Xiangya Hospital of Central South University, Changsha, China.

Jia YaoDepartment of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.

Jingjing WangDepartment of Oncology, The Second Xiangya Hospital of Central South University, Changsha, China. wangjingjing78@csu.edu.cn.

Funding

Changsha Natural Science Foundation kq2208339Changsha Natural Science Foundation kq2403078Chinese Society of Clinical Oncology Y-Young2023-0175Health Commission of Hunan Province 20231607Hunan Natural Science Foundation 2025JJ60486Natural Science Foundation of Hunan Province 2023JJ60429

6 · The paper itself

Abstract

Nimotuzumab is a monoclonal antibody against EGFR. The therapeutic efficacy of nimotuzumab in cervical cancer treatment remains inconclusive, with current evidence insufficient to establish a definitive clinical benefit. Therefore, this study compares the efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy (CCRT) and CCRT in locally advanced cervical cancer (LACC). Information on patients with stage IIB-IVA cervical cancer who received CCRT combined with nimotuzumab or CCRT alone at five cancer centers from January 2021 to December 2022 were collected. Propensity score (PS) matching analysis was used to compare nimotuzumab group and no-nimotuzumab group. Clinical outcomes were analyzed. There were 195 patients enrolled. The 2-year overall survival (OS) and progression-free survival (PFS) rates were 92.5% and 89.5%, respectively. The objective response rate (ORR) was 90.8%. There were 60 patients in the nimotuzumab group and 135 patients in the no-nimotuzumab group. The nimotuzumab group had a better CR rate (51.7% vs. 26.7%, P = 0.001) and ORR (98.3% vs. 87.4%, p = 0.015) compared to the no-nimotuzumab group. After PS matching, there were 54 patients in each group. There were no significant differences in 2-year OS rate and PFS rate between the two groups before and after matching. However, the nimotuzumab group had also a better CR rate and ORR compared to the no-nimotuzumab group after matching. The incidence of grade 3-4 anemia was relatively higher in nimotuzumab group than in no-nimotuzumab group after matching, while no difference was observed in other adverse events between the two groups. The combination of nimotuzumab and CCRT for LACC improved CR rate and ORR, without increasing side effects, which might become a potential treatment strategy for LACC patients.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalChemoradiotherapyUterine Cervical NeoplasmsAdultAgedFemaleHumansMiddle AgedNeoplasm StagingPrognosisProgression-Free SurvivalRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalnimotuzumabConcurrent chemoradiotherapyLocally advanced cervical cancerNimotuzumabPrognosisSafety

Identifiers

PMID40335598

DOI10.1038/s41598-025-98359-4

PMCPMC12059138

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.